Electrophysiologic changes following treatment with organophosphorus-induced delayed neuropathy-producing agents in the adult hen
dc.contributor.author | Robertson, Donald G. | en_US |
dc.contributor.author | Schwab, Bradley W. | en_US |
dc.contributor.author | Sills, Robert D. | en_US |
dc.contributor.author | Richardson, Rudy J. | en_US |
dc.contributor.author | Anderson, Rebecca J. | en_US |
dc.date.accessioned | 2006-04-07T19:55:46Z | |
dc.date.available | 2006-04-07T19:55:46Z | |
dc.date.issued | 1987-03-15 | en_US |
dc.identifier.citation | Robertson, Donald G., Schwab, Bradley W., Sills, Robert D., Richardson, Rudy J., Anderson, Rebecca J. (1987/03/15)."Electrophysiologic changes following treatment with organophosphorus-induced delayed neuropathy-producing agents in the adult hen." Toxicology and Applied Pharmacology 87(3): 420-429. <http://hdl.handle.net/2027.42/26771> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6WXH-4DBJCJH-DR/2/41c18763b8d607cddab32a04d2eba0a0 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/26771 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=3564017&dopt=citation | en_US |
dc.description.abstract | Although clinical, pathological, and biochemical effects of organophosphorus-induced delayed neuropathy (OPIDN) have been intensively investigated in the adult hen, detailed electrophysiological studies are lacking. Adult white leghorn hens were treated with a single oral dose of either 30 mg/kg tri-2-cresyl phosphate (TOCP), 750 mg/kg TOCP, 4 mg/kg di-n-butyl-2,2-dichlorovinyl phosphate (DBCV), or 30 mg/kg di-n-butyl-2,2-dichlorovinyl phosphinate (DBCV-P). The 750 mg/kg TOCP and DBCV, but not the 30 mg/kg TOCP and DBCV-P, treatments resulted in clinical signs of OPIDN and mild to marked damage of the tibial nerve 21 days after dose. Twenty-four hr lymphocyte neurotoxic esterase (NTE) inhibition was used as an index of brain NTE inhibition for the various organophosphorus compound (OP) treatment. Twenty-four hr lymphocyte NTE inhibition for 30 mg/kg TOCP, 750 mg/kg TOCP, DBCV, and DBCV-P was 54.1, 87.1, 84.8, and 68.3%, respectively. Twenty-one days after dose, the TOCP-treated hens exhibited some abnormalities in conduction velocity and action potential duration in the tibial or sciatic nerves. No abnormalities were observed in action potential parameters of either the DBCV or DBCV-P treatments. Neurotoxic OP (TOCP and DBCV) treatment resulted in decreased refractoriness in the tibial nerve, increased refractoriness in the sciatic nerve, and elevated strength duration threshold for both nerves. These changes were not present in nerves from DBCV-P (a non-neurotoxic NTE inhibitor)-treated hens. These results suggest that refractory period and strength duration abnormalities in peripheral nerve correlated well with the production of OPIDN and are evident without coincident clinical signs or histopathology. | en_US |
dc.format.extent | 3623084 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Electrophysiologic changes following treatment with organophosphorus-induced delayed neuropathy-producing agents in the adult hen | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pathology and Experimental Toxicology, Warner-Lambert/Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105, USA; Toxicology Program, School of Public Health, The University of Michigan, Ann Arbor, Michigan 48105, USA. | en_US |
dc.contributor.affiliationum | Toxicology Program, School of Public Health, The University of Michigan, Ann Arbor, Michigan 48105, USA. | en_US |
dc.contributor.affiliationum | Toxicology Program, School of Public Health, The University of Michigan, Ann Arbor, Michigan 48105, USA. | en_US |
dc.contributor.affiliationum | Toxicology Program, School of Public Health, The University of Michigan, Ann Arbor, Michigan 48105, USA. | en_US |
dc.contributor.affiliationum | Department of Pharmacology, Warner-Lambert/Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105, USA; Toxicology Program, School of Public Health, The University of Michigan, Ann Arbor, Michigan 48105, USA. | en_US |
dc.identifier.pmid | 3564017 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/26771/1/0000323.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0041-008X(87)90247-X | en_US |
dc.identifier.source | Toxicology and Applied Pharmacology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.